Clinical Trials in Montana (MT) | Montana Clinical Drug Trials & Studies

You are viewing Clinical Trials In Montana

Have multiple conditions? Click here

Showing 1-100 of 1063

There are 1063 trials in Montana

Name	City	State	Zip
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor	Missoula	MT	59807
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer	Missoula	MT	59807
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer	Missoula	MT	59807
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases	Missoula	MT	59807
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer	Missoula	MT	59807
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma	Missoula	MT	59807
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Missoula	MT	59807
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	Missoula	MT	59807
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Missoula	MT	59807
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery	Missoula	MT	59807
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy	Missoula	MT	59807
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer	Missoula	MT	59807
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer	Missoula	MT	59807
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer	Missoula	MT	59807
Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Missoula	MT	59807
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer	Missoula	MT	59807
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	Missoula	MT	59807
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery	Missoula	MT	59807
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	Missoula	MT	59807
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct	Missoula	MT	59807
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery	Missoula	MT	59807
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia	Missoula	MT	59807
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Missoula	MT	59807
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma	Missoula	MT	59807
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Missoula	MT	59807
Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia	Missoula	MT	59807
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia	Missoula	MT	59807
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer	Missoula	MT	59807
Acute Pain Caused by Paclitaxel in Patients With Cancer	Missoula	MT	59807
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery	Missoula	MT	59807
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Missoula	MT	59807
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement	Missoula	MT	59807
Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Missoula	MT	59807
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases	Missoula	MT	59807
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer	Missoula	MT	59807
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer	Missoula	MT	59807
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer	Missoula	MT	59807
Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial	Missoula	MT	59807
Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma	Missoula	MT	59807
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma	Missoula	MT	59807
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer	Missoula	MT	59807
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary	Missoula	MT	59807
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction	Missoula	MT	59807
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	Missoula	MT	59807
Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia	Missoula	MT	59807
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	Missoula	MT	59807
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Missoula	MT	59807
Vorinostat, Rituximab, and Combination Chemotherapy In Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma	Missoula	MT	59807
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma	Missoula	MT	59807
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer	Missoula	MT	59807
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers	Missoula	MT	59807
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma	Missoula	MT	59807
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery	Missoula	MT	59807
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia	Missoula	MT	59807
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Missoula	MT	59807
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	Missoula	MT	59807
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer	Missoula	MT	59807
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma	Missoula	MT	59807
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer	Missoula	MT	59807
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer	Missoula	MT	59807
RO4929097 in Treating Patients With Stage IV Melanoma	Missoula	MT	59807
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer	Missoula	MT	59807
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery	Missoula	MT	59807
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Missoula	MT	59807
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma	Missoula	MT	59807
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	Missoula	MT	59807
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery	Missoula	MT	59807
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer	Missoula	MT	59807
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor	Missoula	MT	59807
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer	Missoula	MT	59807
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer	Missoula	MT	59807
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases	Missoula	MT	59807
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer	Missoula	MT	59807
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer	Missoula	MT	59807
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma	Missoula	MT	59807
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Missoula	MT	59807
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	Missoula	MT	59807
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Missoula	MT	59807
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery	Missoula	MT	59807
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy	Missoula	MT	59807
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer	Missoula	MT	59807
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer	Missoula	MT	59807
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer	Missoula	MT	59807
Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Missoula	MT	59807
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer	Missoula	MT	59807
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	Missoula	MT	59807
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery	Missoula	MT	59807
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	Missoula	MT	59807
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct	Missoula	MT	59807
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery	Missoula	MT	59807
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia	Missoula	MT	59807
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Missoula	MT	59807
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma	Missoula	MT	59807
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Missoula	MT	59807
Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia	Missoula	MT	59807
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia	Missoula	MT	59807
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer	Missoula	MT	59807
Acute Pain Caused by Paclitaxel in Patients With Cancer	Missoula	MT	59807
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery	Missoula	MT	59807
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Missoula	MT	59807

View Clinical Trial Facilities in Montana

Showing 1-100 of 1063